Seshu Tyagarajan Sells 31,278 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan sold 31,278 shares of Candel Therapeutics stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $8.82, for a total value of $275,871.96. Following the transaction, the chief technology officer now owns 85,512 shares of the company’s stock, valued at $754,215.84. This represents a 26.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Seshu Tyagarajan also recently made the following trade(s):

• On Wednesday, January 15th, Seshu Tyagarajan sold 14,322 shares of Candel Therapeutics stock. The shares were sold at an average price of $7.22, for a total value of $103,404.84.

Candel Therapeutics Trading Up 0.9 %

NASDAQ CADL traded up $0.08 during trading on Wednesday, reaching $8.90. The company’s stock had a trading volume of 640,009 shares, compared to its average volume of 2,651,855. Candel Therapeutics, Inc. has a 12 month low of $1.40 and a 12 month high of $14.60. The firm has a 50 day moving average price of $8.23 and a 200 day moving average price of $6.98. The firm has a market capitalization of $289.04 million, a price-to-earnings ratio of -5.14 and a beta of -1.29.

Candel Therapeutics (NASDAQ:CADL) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.17). On average, equities analysts forecast that Candel Therapeutics, Inc. will post -1.47 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on CADL shares. HC Wainwright reissued a “buy” rating and issued a $19.00 price objective on shares of Candel Therapeutics in a research report on Friday, March 14th. Bank of America started coverage on shares of Candel Therapeutics in a research report on Friday, February 7th. They set a “buy” rating and a $15.00 price objective for the company. Canaccord Genuity Group increased their target price on Candel Therapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, February 26th. Finally, Citigroup initiated coverage on Candel Therapeutics in a research note on Thursday, February 20th. They issued a “buy” rating and a $25.00 price target for the company.

Institutional Investors Weigh In On Candel Therapeutics

A number of large investors have recently bought and sold shares of the company. MetLife Investment Management LLC lifted its holdings in shares of Candel Therapeutics by 9.7% during the 4th quarter. MetLife Investment Management LLC now owns 13,773 shares of the company’s stock worth $120,000 after acquiring an additional 1,215 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Candel Therapeutics by 12.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,165 shares of the company’s stock worth $106,000 after purchasing an additional 1,340 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Candel Therapeutics by 15.2% in the 4th quarter. JPMorgan Chase & Co. now owns 10,426 shares of the company’s stock valued at $90,000 after purchasing an additional 1,375 shares in the last quarter. Russell Investments Group Ltd. increased its stake in shares of Candel Therapeutics by 75.1% in the 4th quarter. Russell Investments Group Ltd. now owns 3,753 shares of the company’s stock valued at $33,000 after purchasing an additional 1,610 shares during the last quarter. Finally, Nuveen Asset Management LLC lifted its position in shares of Candel Therapeutics by 3.0% during the 4th quarter. Nuveen Asset Management LLC now owns 68,226 shares of the company’s stock worth $592,000 after buying an additional 2,009 shares during the last quarter. 13.93% of the stock is currently owned by institutional investors and hedge funds.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.